{
    "ticker": "ALLO",
    "name": "Allogene Therapeutics, Inc.",
    "description": "Allogene Therapeutics, Inc. is a biotechnology company dedicated to the development of innovative allogeneic T cell therapies for the treatment of cancer. Founded in 2018, Allogene is at the forefront of cellular medicine, leveraging its proprietary technology to create off-the-shelf therapies designed to harness the power of the immune system to fight cancer. The company\u2019s lead product candidate, ALLO-501, is an investigational therapy targeting CD19, aiming to treat patients with hematologic malignancies. Allogene's unique approach involves using genetically engineered T cells from healthy donors, which can be manufactured at scale and administered to patients without the need for complex and time-consuming processes typically associated with autologous therapies. The company is committed to advancing its pipeline of next-generation therapies and improving patient outcomes through its research and development efforts. With a strong focus on collaboration, Allogene partners with leading institutions and organizations to accelerate its clinical programs and bring transformative therapies to market. The company\u2019s mission is to provide accessible and effective cancer treatments that can improve the quality of life for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2018",
    "website": "https://www.allogene.com",
    "ceo": "David Chang",
    "social_media": {
        "twitter": "https://twitter.com/AllogeneTx",
        "linkedin": "https://www.linkedin.com/company/allogene-therapeutics/"
    },
    "investor_relations": "https://investors.allogene.com",
    "key_executives": [
        {
            "name": "David Chang",
            "position": "CEO"
        },
        {
            "name": "Jennifer S. Louie",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapies",
            "products": [
                "ALLO-501",
                "ALLO-715"
            ]
        }
    ],
    "seo": {
        "meta_title": "Allogene Therapeutics, Inc. | Innovative Allogeneic T Cell Therapies",
        "meta_description": "Explore Allogene Therapeutics, Inc., a leader in developing allogeneic T cell therapies for cancer treatment. Learn about our innovative approaches and pipeline.",
        "keywords": [
            "Allogene Therapeutics",
            "T cell therapy",
            "cancer treatment",
            "biotechnology",
            "ALLO-501",
            "ALLO-715"
        ]
    },
    "faq": [
        {
            "question": "What does Allogene Therapeutics focus on?",
            "answer": "Allogene Therapeutics focuses on developing allogeneic T cell therapies for cancer treatment."
        },
        {
            "question": "Who is the CEO of Allogene Therapeutics?",
            "answer": "David Chang is the CEO of Allogene Therapeutics, Inc."
        },
        {
            "question": "Where is Allogene Therapeutics headquartered?",
            "answer": "Allogene Therapeutics is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Allogene's main product candidates?",
            "answer": "Allogene's main product candidates include ALLO-501 and ALLO-715, both targeting different forms of cancer."
        },
        {
            "question": "When was Allogene Therapeutics founded?",
            "answer": "Allogene Therapeutics was founded in 2018."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGMO"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "BIIB",
        "VRTX"
    ]
}